Myositis of the skeletal muscle is rarely seen as an extraintestinal manifestation of inflammatory bowel disease. We report a case of a 36-year-old man with ulcerative colitis who developed 3 episodes of steroid responsive myositis in a 4-month period. He presented with a blistering rash followed by pain and massive swelling in the right shoulder and lower extremities, with marked elevation in muscle enzymes. Diagnosis of myositis was made after a muscle biopsy, which showed neutrophilic infiltrate in the deep subcutaneous tissue and skeletal muscle. Review of the literature indicates only a few cases of myositis associated with ulcerative colitis, most of them during an acute exacerbation of the disease. However, the present patient had his first episode when the ulcerative colitis was in remission. Myositis in ulcerative colitis may present atypically, in particular mimicking pyomyositis. Clinicians should be aware of this unusual steroid-sensitive complication.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00124743-200204000-00004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Anemia classification, prevalence and predictive factors in inflammatory bowel disease].
Orv Hetil
January 2025
1 Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika Budapest, Korányi S. u. 2/a, 1083 Magyarország.
Inflammatory bowel disease increases the risk of pancreatitis: a two-sample bidirectional Mendelian randomization analysis.
BMC Gastroenterol
January 2025
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Background: Previous studies have suggested an association between inflammatory bowel disease (IBD), and pancreatitis, including acute pancreatitis (AP) and chronic pancreatitis (CP). We aimed to examine the potential causal relationship between IBD and pancreatitis using the Mendelian randomization (MR) method.
Methods: We obtained data from genome-wide association studies (GWASs) in European individuals for IBD and its main subtypes, Crohn's disease (CD) and ulcerative colitis (UC) (31,665 IBD cases, 13,768 UC cases, 17,897 CD cases and 33,977 controls).
Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis.
Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Background: Mesalamine is the first-line drug for treating mild-to-moderate ulcerative colitis (UC); however, some patients develop symptoms of intolerance. Although several desensitization methods have been reported, these desensitization regimens were rather complicated for physicians to prescribe in daily clinical practice; therefore, it has not yet become a major therapeutic option for intolerance patients. Thus, we developed an alternative desensitization protocol.
View Article and Find Full Text PDFThe Effects of 5-Aminosalicylic Acid on Janus Kinase Inhibitor Treatment in Ulcerative Colitis.
J Gastroenterol Hepatol
January 2025
Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.
Proposal and exploration of a novel score to quantify patient-perceived burden of inflammatory bowel disease under routine care.
Intern Med J
January 2025
Crohn's Colitis Cure, Sydney, New South Wales, Australia.
Background: The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort.
Aim: To create and explore a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort, and correlate PPBoD scores with demographics, disease and treatment factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!